Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The data highlights its RSV vaccine cuts hospitalizations in older adults
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Subscribe To Our Newsletter & Stay Updated